CN109096274B - 可用于治疗人类肿瘤学、神经病学和免疫学疾病的联芳基化合物 - Google Patents

可用于治疗人类肿瘤学、神经病学和免疫学疾病的联芳基化合物 Download PDF

Info

Publication number
CN109096274B
CN109096274B CN201810840784.7A CN201810840784A CN109096274B CN 109096274 B CN109096274 B CN 109096274B CN 201810840784 A CN201810840784 A CN 201810840784A CN 109096274 B CN109096274 B CN 109096274B
Authority
CN
China
Prior art keywords
methyl
pyrimidin
amino
tert
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810840784.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN109096274A (zh
Inventor
B.T.霍普金斯
B.马
T.R.陈
L.孙
L.张
G.库马拉维尔
J.P.利斯西卡托斯
K.科赫
H.苗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Than Ao Gen Ma Co
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of CN109096274A publication Critical patent/CN109096274A/zh
Application granted granted Critical
Publication of CN109096274B publication Critical patent/CN109096274B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201810840784.7A 2013-12-11 2014-12-11 可用于治疗人类肿瘤学、神经病学和免疫学疾病的联芳基化合物 Active CN109096274B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361914886P 2013-12-11 2013-12-11
US61/914,886 2013-12-11
CN201480071422.6A CN106459002B (zh) 2013-12-11 2014-12-11 可用于治疗人类肿瘤学、神经病学和免疫学疾病的联芳基化合物
PCT/US2014/069853 WO2015089337A1 (en) 2013-12-11 2014-12-11 Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480071422.6A Division CN106459002B (zh) 2013-12-11 2014-12-11 可用于治疗人类肿瘤学、神经病学和免疫学疾病的联芳基化合物

Publications (2)

Publication Number Publication Date
CN109096274A CN109096274A (zh) 2018-12-28
CN109096274B true CN109096274B (zh) 2022-07-01

Family

ID=52302344

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201810840784.7A Active CN109096274B (zh) 2013-12-11 2014-12-11 可用于治疗人类肿瘤学、神经病学和免疫学疾病的联芳基化合物
CN201480071422.6A Active CN106459002B (zh) 2013-12-11 2014-12-11 可用于治疗人类肿瘤学、神经病学和免疫学疾病的联芳基化合物
CN201810840975.3A Pending CN108947913A (zh) 2013-12-11 2014-12-11 可用于治疗人类肿瘤学、神经病学和免疫学疾病的联芳基化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201480071422.6A Active CN106459002B (zh) 2013-12-11 2014-12-11 可用于治疗人类肿瘤学、神经病学和免疫学疾病的联芳基化合物
CN201810840975.3A Pending CN108947913A (zh) 2013-12-11 2014-12-11 可用于治疗人类肿瘤学、神经病学和免疫学疾病的联芳基化合物

Country Status (32)

Country Link
US (4) US9809577B2 (enExample)
EP (3) EP3357921A3 (enExample)
JP (4) JP6431914B2 (enExample)
KR (1) KR102413253B1 (enExample)
CN (3) CN109096274B (enExample)
AR (2) AR098721A1 (enExample)
AU (2) AU2014362231B2 (enExample)
BR (1) BR112016012860A2 (enExample)
CA (1) CA2932608C (enExample)
CL (2) CL2016001435A1 (enExample)
CY (1) CY1120517T1 (enExample)
DK (1) DK3080103T3 (enExample)
EA (2) EA030538B1 (enExample)
ES (1) ES2678021T3 (enExample)
HR (1) HRP20181109T1 (enExample)
HU (1) HUE040346T2 (enExample)
IL (2) IL246031B (enExample)
LT (1) LT3080103T (enExample)
MX (2) MX370103B (enExample)
MY (1) MY179781A (enExample)
NZ (1) NZ721217A (enExample)
PH (1) PH12016501107B1 (enExample)
PL (1) PL3080103T3 (enExample)
PT (1) PT3080103T (enExample)
RS (1) RS57662B1 (enExample)
SA (1) SA518391170B1 (enExample)
SG (2) SG10201908558WA (enExample)
SI (1) SI3080103T1 (enExample)
SM (1) SMT201800373T1 (enExample)
TW (3) TWI744672B (enExample)
WO (1) WO2015089337A1 (enExample)
ZA (1) ZA201706244B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI711610B (zh) * 2009-09-04 2020-12-01 美商百健Ｍａ公司 布魯頓氏酪胺酸激酶抑制劑
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
US9809577B2 (en) 2013-12-11 2017-11-07 Biogen Ma Inc. Biaryl inhibitors of Bruton's tyrosine kinase
MA42510A (fr) 2015-06-10 2018-06-06 Biogen Ma Inc Formes et compositions d'inhibiteurs biaryles de la tyrosine kinase de bruton
CA2988576A1 (en) * 2015-06-10 2016-12-15 Biogen Ma Inc. Adipate forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
WO2017097216A1 (zh) * 2015-12-07 2017-06-15 杭州雷索药业有限公司 五元杂环酰胺类wnt通路抑制剂
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
JO3793B1 (ar) * 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
EP3436572A4 (en) * 2016-03-31 2019-11-20 Lion TCR Pte. Ltd. EXOGENOUS VIRUS-SPECIFIC T-CELL RECEPTOR (TCR) EXPRESSIVE UNACTIVATED T-CELLS
EP3476848A4 (en) * 2016-06-27 2020-01-15 Hangzhou Rex Pharmaceutical Co., Ltd BENZOFURANE-PYRAZOLE-AMINE PROTEIN KINASE INHIBITOR
CN110049976A (zh) 2016-07-21 2019-07-23 比奥根Ma公司 布鲁顿氏酪氨酸激酶抑制剂的琥珀酸盐形式和组合物
US10954216B2 (en) 2016-12-27 2021-03-23 Riken BMP-signal-inhibiting compound
JOP20190233A1 (ar) 2017-04-14 2019-10-02 Biogen Ma Inc نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
US11466012B2 (en) 2018-01-10 2022-10-11 Allinky Biopharma Tetrahydroisoquinoline compounds
EP3740481B9 (en) 2018-01-19 2024-10-23 Cytokinetics, Inc. Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
US20190330226A1 (en) * 2018-04-26 2019-10-31 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
ES2968222T3 (es) * 2018-05-14 2024-05-08 Biogen Ma Inc Agentes inhibidores para la tirosina cinasa de Bruton
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
EP3814342B1 (en) 2018-06-26 2022-07-27 Cytokinetics, Inc. Cardiac sarcomere inhibitors
KR102545594B1 (ko) 2018-07-31 2023-06-21 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의 분무-건조된 분산물 및 제제
US11820760B2 (en) 2018-10-15 2023-11-21 Biogen Ma Inc. Crystalline polymorphs of Bruton's tyrosine kinase inhibitors
WO2020118683A1 (en) * 2018-12-14 2020-06-18 Lynk Pharmaceuticals Co. Ltd. Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
JP7747523B2 (ja) * 2019-05-15 2025-10-01 バイオジェン・エムエイ・インコーポレイテッド ブルトン型チロシンキナーゼの阻害剤
CN110627775A (zh) * 2019-10-24 2019-12-31 嘉兴特科罗生物科技有限公司 一种小分子化合物
JP7646671B2 (ja) * 2019-12-23 2025-03-17 バイオジェン・エムエイ・インコーポレイテッド Ｂｔｋ阻害剤
UY39370A (es) 2020-08-07 2022-02-25 Biogen Ma Inc Inhibidores de la btk
CN116917279A (zh) * 2020-08-07 2023-10-20 渤健马萨诸塞州股份有限公司 Btk抑制剂
EP4313023A1 (en) 2021-04-02 2024-02-07 Biogen MA Inc. Combination treatment methods of multiple sclerosis
JP2024525181A (ja) * 2021-06-21 2024-07-10 ベイジーン スウィッツァーランド ゲーエムベーハー （ｒ）－グルタルイミドｃｒｂｎリガンド及び使用方法
IL313509A (en) * 2021-12-30 2024-08-01 Beigene Switzerland Gmbh Reduction of proton tyrosine kinase (btk) by fusing btk inhibitors with an e3 ligase ligand and methods of use
CN116891437B (zh) * 2022-04-06 2025-10-28 长春金赛药业有限责任公司 氨基酸衍生物、药物组合物及其制备方法和应用
WO2024146923A1 (en) 2023-01-04 2024-07-11 Ab Science Tubulin polymerization inhibitors
CN117088851A (zh) * 2023-07-13 2023-11-21 特科罗生物科技(成都)有限公司 一种嘧啶胺类nuak抑制剂及其制备方法和用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101730699A (zh) * 2007-03-21 2010-06-09 百时美施贵宝公司 可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物
WO2011029043A1 (en) * 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Heteroaryl btk inhibitors
WO2011029046A1 (en) * 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Bruton's tyrosine kinase inhibitors
US20120296089A1 (en) * 2007-03-28 2012-11-22 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US8334292B1 (en) * 2010-06-14 2012-12-18 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
CN104119336A (zh) * 2007-10-05 2014-10-29 维拉斯通股份有限公司 嘧啶取代的嘌呤衍生物
CN104540385A (zh) * 2012-06-08 2015-04-22 比奥根艾迪克Ma公司 嘧啶基酪氨酸激酶抑制剂

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US833429A (en) * 1902-07-31 1906-10-16 Anthony Van Wagenen Automatic system of intercommunication.
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
EP0495421B1 (en) 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9924862D0 (en) * 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
HK1054033A1 (zh) * 2000-08-08 2003-11-14 Ortho-Mcneil Pharmaceutical, Inc. 4-嘧啶胺衍生物、药用组合物和相关方法
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
GB0325031D0 (en) * 2003-10-27 2003-12-03 Novartis Ag Organic compounds
JP2007519754A (ja) * 2004-01-30 2007-07-19 スミスクライン ビーチャム コーポレーション 化合物
US20060178388A1 (en) * 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
MY167260A (en) * 2005-11-01 2018-08-14 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
CN101370792B (zh) * 2005-11-01 2013-03-20 塔格根公司 激酶的联-芳基间-嘧啶抑制剂
EP1979329A2 (en) 2006-01-30 2008-10-15 Exelixis, Inc. 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and methods of use
AR063946A1 (es) * 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
WO2008053182A1 (en) * 2006-11-01 2008-05-08 Chroma Therapeutics Ltd. IKK-β SERINE-THREONINE PROTEIN KINASE INHIBITORS
EP2362775B1 (en) * 2008-11-20 2015-08-05 GlaxoSmithKline LLC Chemical compounds
WO2012062704A1 (en) 2010-11-09 2012-05-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors
EP2548622B1 (en) 2011-03-31 2015-06-17 Mizuno Corporation Iron golf club head and iron golf club
CN103732067A (zh) 2011-04-12 2014-04-16 美国阿尔茨海默病研究所公司 化合物，组合物及它们的治疗用途
US10280169B2 (en) 2013-12-11 2019-05-07 Biogen Ma Inc. Biaryl bruton's tyrosine kinase inhibitors
US9809577B2 (en) * 2013-12-11 2017-11-07 Biogen Ma Inc. Biaryl inhibitors of Bruton's tyrosine kinase
SG11201609981RA (en) * 2014-06-04 2016-12-29 Thomas Helledays Stiftelse För Medicinsk Forskning Mth1 inhibitors for treatment of inflammatory and autoimmune conditions
UA125061C2 (uk) * 2014-10-06 2022-01-05 Мерк Патент Ґмбг Сполуки гетероарилу як інгібітори ткб і їх застосування
MA42510A (fr) 2015-06-10 2018-06-06 Biogen Ma Inc Formes et compositions d'inhibiteurs biaryles de la tyrosine kinase de bruton
JOP20190233A1 (ar) 2017-04-14 2019-10-02 Biogen Ma Inc نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101730699A (zh) * 2007-03-21 2010-06-09 百时美施贵宝公司 可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物
US20120296089A1 (en) * 2007-03-28 2012-11-22 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
CN104119336A (zh) * 2007-10-05 2014-10-29 维拉斯通股份有限公司 嘧啶取代的嘌呤衍生物
WO2011029043A1 (en) * 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Heteroaryl btk inhibitors
WO2011029046A1 (en) * 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Bruton's tyrosine kinase inhibitors
US8334292B1 (en) * 2010-06-14 2012-12-18 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
CN104540385A (zh) * 2012-06-08 2015-04-22 比奥根艾迪克Ma公司 嘧啶基酪氨酸激酶抑制剂

Also Published As

Publication number Publication date
CA2932608A1 (en) 2015-06-18
EA201792348A1 (ru) 2018-09-28
JP2019163280A (ja) 2019-09-26
HRP20181109T1 (hr) 2018-11-02
CY1120517T1 (el) 2019-07-10
JP6526167B2 (ja) 2019-06-05
AU2019201997B2 (en) 2020-09-17
ES2678021T3 (es) 2018-08-08
CA2932608C (en) 2023-02-14
AU2019201997A1 (en) 2019-04-18
AR098721A1 (es) 2016-06-08
JP2016539996A (ja) 2016-12-22
CL2017001459A1 (es) 2018-03-23
KR20160106072A (ko) 2016-09-09
MX388978B (es) 2025-03-20
AU2019201997C1 (en) 2021-03-18
AR110381A2 (es) 2019-03-20
TWI675833B (zh) 2019-11-01
SA518391170B1 (ar) 2022-08-25
EP3080103B1 (en) 2018-04-18
TW201536765A (zh) 2015-10-01
IL269569A (en) 2019-11-28
RS57662B1 (sr) 2018-11-30
IL246031A0 (en) 2016-08-02
CN106459002A (zh) 2017-02-22
AU2014362231B2 (en) 2019-04-04
EP3357921A2 (en) 2018-08-08
KR102413253B1 (ko) 2022-06-27
EP3080103A1 (en) 2016-10-19
IL246031B (en) 2019-10-31
US20220332705A1 (en) 2022-10-20
JP6431914B2 (ja) 2018-11-28
MX2016007611A (es) 2016-09-09
HUE040346T2 (hu) 2019-03-28
LT3080103T (lt) 2018-08-10
JP2021091733A (ja) 2021-06-17
ZA201706244B (en) 2019-04-24
EP3080103B9 (en) 2018-09-19
AU2014362231A1 (en) 2016-07-07
US10759783B2 (en) 2020-09-01
US10081619B2 (en) 2018-09-25
TW201811772A (zh) 2018-04-01
SMT201800373T1 (it) 2018-09-13
WO2015089337A1 (en) 2015-06-18
CN109096274A (zh) 2018-12-28
EA030538B1 (ru) 2018-08-31
US20190218204A1 (en) 2019-07-18
DK3080103T3 (en) 2018-07-30
TWI608002B (zh) 2017-12-11
PH12016501107A1 (en) 2016-07-11
US11572356B2 (en) 2023-02-07
EP3872075A1 (en) 2021-09-01
US20180093973A1 (en) 2018-04-05
NZ721217A (en) 2021-12-24
PH12016501107B1 (en) 2021-07-21
TW202017931A (zh) 2020-05-16
BR112016012860A2 (pt) 2017-08-08
IL269569B (en) 2021-03-25
MY179781A (en) 2020-11-13
MX370103B (es) 2019-12-02
EA037942B1 (ru) 2021-06-10
CL2016001435A1 (es) 2017-06-09
SG11201604595VA (en) 2016-07-28
TWI744672B (zh) 2021-11-01
PT3080103T (pt) 2018-07-23
SG10201908558WA (en) 2019-10-30
US9809577B2 (en) 2017-11-07
SI3080103T1 (sl) 2018-11-30
PL3080103T3 (pl) 2018-10-31
CN108947913A (zh) 2018-12-07
EA201691114A1 (ru) 2016-11-30
EP3357921A3 (en) 2018-09-12
US20160311802A1 (en) 2016-10-27
JP7076022B2 (ja) 2022-05-26
CN106459002B (zh) 2018-08-21
JP2018035201A (ja) 2018-03-08
MX2019014228A (es) 2020-01-23

Similar Documents

Publication Publication Date Title
CN109096274B (zh) 可用于治疗人类肿瘤学、神经病学和免疫学疾病的联芳基化合物
KR101712576B1 (ko) Ａｔｒ 키나제의 억제제로서 유용한 화합물
KR102007796B1 (ko) Bet 브로모도메인 저해제로서 테트라하이드로퀴놀린 조성물
EP4267574B1 (en) 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
HK40001576A (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
HK40058075A (en) Intermediates and processes for the preparation of biaryl compounds
HK1229333B (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
HK1229333A1 (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20191107

Address after: Massachusetts, USA

Applicant after: Than Ao Gen MA company

Address before: Massachusetts, USA

Applicant before: Than Ao Gen MA company

Applicant before: Sunisis Pharmaceutical Co., Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant